Transfusion Management in Thalassemia
1. Introduction
Thalassemia is a hereditary hemoglobin disorder caused by reduced or absent synthesis of the globin chain. The clinical spectrum ranges from the severe transfusiondependent thalassemia major to the milder thalassemia intermedia, which may require occasional transfusions. Regular blood transfusion remains the cornerstone of diseasemodifying therapy for patients with severe disease, aiming to suppress ineffective erythropoiesis, prevent skeletal deformities, and improve growth, endocrine function, and overall quality of life.
2. Goals of Transfusion Therapy
- Hemoglobin Target: Maintain pretransfusion hemoglobin (Hb) between 9.5 and 12g/dL (most centers aim for 1011g/dL).
- Suppression of Marrow Expansion: Reduce extramedullary hematopoiesis and prevent bone changes.
- Delay of Complications: Lower risk of cardiac failure, pulmonary hypertension, and endocrine dysfunction.
- Optimisation of Iron Load Management: Balance transfusion benefit with ironoverload prevention.
3. Determining the Transfusion Schedule
3.1 Frequency
Most patients receive red cell transfusions every 24weeks. The interval is individualized based on Hb trends, growth velocity, and patient tolerance.
3.2 Volume
Typical dose: 1015mL/kg of packed red blood cells (PRBC) per transfusion. In children, the dose may be split into two sessions to improve tolerability.
3.3 Pretransfusion Testing
- ABO/Rh typing and antibody screen.
- Baseline CBC and reticulocyte count.
- Serum ferritin and liver iron concentration (if available) to gauge iron load.
4. Matching and Blood Product Selection
| Requirement | Recommended Product |
|---|---|
| Standard transfusion | Leukoreduced, irradiated PRBCs (if patient is splenectomised or at risk of graftversushost disease) |
| Patients with alloantibodies | Extended phenotypically matched (Rh, Kell, Duffy, MNS) or genotypically matched units |
| Highrisk patients | CMVnegative, pathogenreduced units |
5. Managing AlloImmunisation
Alloimmunisation occurs in up to 30% of regularly transfused thalassemia patients. Strategies to minimise risk include:
- Providing phenotypematched blood from the first transfusion.
- Using leukoreduced products to reduce immune activation.
- Maintaining a detailed transfusion record to track antibodies.
- Considering donor registries that include extended antigen matching for highrisk individuals.
6. Iron Overload Prevention and Treatment
6.1 Monitoring
Ferritin is measured every 36months; values >1,000ng/mL suggest significant iron burden. MRIbased T2* of the heart and liver provides quantitative iron assessment and guides chelation intensity.
6.2 Chelation Therapy
| Agent | Typical Dose | Route | Key Adverse Effects |
|---|---|---|---|
| Deferoxamine (DFO) | 2040mg/kg/day | Subcutaneous infusion (812h/night) | Auditory/ocular toxicity, growth retardation |
| Deferiprone (DFP) | 75100mg/kg/day divided TID | Oral | Neutropenia, agranulocytosis, GI upset |
| Deferasirox (DFX) | 2030mg/kg/day | Oral | Renal dysfunction, hepatic elevation, GI symptoms |
Combination chelation (DFO+DFP or DFO+DFX) is employed when monotherapy fails to control iron load.
7. Surveillance for TransfusionRelated Complications
- Infectious Risks: Ongoing screening of donor blood for HIV, HBV, HCV, and emerging pathogens.
- Transfusion Reactions: Acute hemolysis, febrile nonhemolytic reactions, allergic responsesmonitor vitals during each session.
- Volume Overload: Particularly in adult patients; assess for signs of congestive heart failure.
- Endocrine Disturbances: Early detection of hypogonadism, hypothyroidism, and diabetes, which may be exacerbated by iron overload.
8. Special Situations
8.1 Pregnancy
Pregnant women with thalassemia major often need increased transfusion frequency to maintain Hb10g/dL, reducing fetal hypoxia and maternal cardiac strain. Chelation is stopped during pregnancy; iron overload is managed postpartum.
8.2 Splenectomy
After splenectomy, transfusion requirements often fall, but the risk of alloimmunisation rises, so extended antigen matching becomes even more crucial.
8.3 Stem Cell Transplant / Gene Therapy Candidates
Patients preparing for curative therapies should minimise iron burden and avoid alloantibody formation to improve transplant outcomes.
9. Patient Education and SelfManagement
Empowering patients with knowledge about the importance of adherence to transfusion schedules, chelation therapy, and routine monitoring improves longterm outcomes. Suggested educational points:
- Keep a transfusion diary noting dates, volumes, and any reactions.
- Take chelation exactly as prescribed; report signs of infection or unusual bruising promptly.
- Maintain regular appointments for ferritin, MRI, and endocrine assessments.
- Adopt a balanced diet low in ironenhancing foods when appropriate.
10. Future Directions
Emerging strategies aim to reduce transfusion dependence:
- Luspatercept: An activinreceptor ligand trap that promotes latestage erythroid maturationshowing promising reductions in transfusion needs in clinical trials.
- Gene Editing (CRISPR/Cas9) and Gene Addition: Early phase studies suggest durable correction of globin synthesis, potentially eliminating lifelong transfusion.
- Improved IronChelation Formulations: Longacting oral agents and targeted delivery systems are under investigation to enhance compliance.
Transfusion Management Of Beta Thalassemia and Reference File Download Link
Safe Blood Transfusion Practices And Nursing Scope Of Practice and Reference File Download...